Avon Donates $20 Million to NCI for Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

BETHESDA, Maryland-The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

BETHESDA, Maryland—The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

The foundation also awarded $10 million each to the Massachusetts General Hospital/Harvard Comprehensive Cancer Center, the University of California, San Francisco Comprehensive Cancer Center, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. It said the funds would be used at each institution to support biomedical research, clinical care for medically underserved women, and construction of new facilities focusing on breast cancer research and care.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table